Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Palomo

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|March 12, 2024
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyAleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, et al.
Haematologica|March 13, 2025
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemiaDaniel Medina-Gil, Laura Palomo, Víctor Navarro, et al.
British Journal of Haematology|May 26, 2018
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemiaAna M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, et al.
British Journal of Haematology|October 18, 2019
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemiaLaura Palomo, Mariam Ibáñez, María Abáigar, et al.
Oncotarget|January 16, 2016
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancerFelix Royo, Patricia Zuñiga-Garcia, Verónica Torrano, et al.
Blood Advances|July 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasmsOriol Calvete, Julia Mestre, Lorea Chaparro-González, et al.
Blood Advances|October 10, 2024
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecularSandra Castaño-Díez, Mònica López-Guerra, Inés Zugasti, et al.
Blood|July 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionMaria Julia Montoro, Laura Palomo, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|March 12, 2024
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyAleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, et al.
Haematologica|March 13, 2025
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemiaDaniel Medina-Gil, Laura Palomo, Víctor Navarro, et al.
British Journal of Haematology|May 26, 2018
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemiaAna M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, et al.
British Journal of Haematology|October 18, 2019
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemiaLaura Palomo, Mariam Ibáñez, María Abáigar, et al.
Oncotarget|January 16, 2016
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancerFelix Royo, Patricia Zuñiga-Garcia, Verónica Torrano, et al.
Blood Advances|July 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasmsOriol Calvete, Julia Mestre, Lorea Chaparro-González, et al.
Blood Advances|October 10, 2024
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecularSandra Castaño-Díez, Mònica López-Guerra, Inés Zugasti, et al.
Blood|July 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionMaria Julia Montoro, Laura Palomo, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Pageof 5